Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges

被引：0
|
作者：
Volpe, Massimo [1 ]
Patrono, Carlo [2 ]
机构：
[1] Sapienza Univ Rome, St Andrea Hosp, Dept Cardiol, Rome, Italy
[2] Catholic Univ, Sch Med, Dept Pharmacol, Rome, Italy
来源：
EUROPEAN HEART JOURNAL | 2023年 / 44卷 / 03期
关键词：
SACUBITRIL/VALSARTAN;
D O I：
10.1093/eurheartj/ehac649
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：178 / 179
页数：2
相关论文
共 50 条
  • [41] Uptake of SGLT2i therapyamongpatients hospitalized with heart failure: Insights from the veterans affairs healthcare system
    Calma, J.
    Varshney, A. S.
    Hernandez, M. Funes
    Hsiao, S.
    Sallam, K.
    Heidenreich, P. A.
    Sandhu, A. T.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [42] Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction
    De Marzo, Vincenzo
    Savarese, Gianluigi
    Porto, Italo
    Metra, Marco
    Ameri, Pietro
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2023, 24 (08) : 537 - 543
  • [43] SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
    Volpe, Massimo
    Pedicino, Daniela
    EUROPEAN HEART JOURNAL, 2022, 43 (44) : 4614 - 4615
  • [44] Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF
    Bocchi, Edimar Alcides
    Biolo, Andrea
    Moura, Lidia Zytynski
    Figueiredo Neto, Jose Albuquerque
    Lucena Montenegro, Carlos Eduardo
    de Albuquerque, Denilson Campos
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2021, 116 (02)
  • [45] STRATEGIES TO OPTIMISE GUIDELINE-DIRECTED MEDICAL THERAPY IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION BY IMPROVING SGLT2I INITIATION RATES IN NURSE-LED OUTPATIENT HEART FAILURE CLINICS
    Soh, Bwt
    Cusack, R.
    O'Brien, K.
    Glasgow, J.
    Forkin, A.
    Abbas, S.
    Arnous, S.
    Kiernan, T.
    HEART, 2022, 108 : A51 - A53
  • [46] Cardiac sodium/hydrogen exchanger (NHE11) as a novel potential target for SGLT2i in heart failure
    Perez-Carrillo, L.
    Gimenez-Escamilla, I.
    Feijoo-Bandin, S.
    Lago, F.
    Gonzalez-Juanatey, J. R.
    Martinez-Dolz, L.
    Portoles, M.
    Tarazon, E.
    Rosello-Lleti, E.
    EUROPEAN HEART JOURNAL, 2022, 43 : 751 - 751
  • [47] Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care
    Packer, Milton
    EUROPEAN HEART JOURNAL, 2020, 41 (25) : 2393 - 2396
  • [48] Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?
    Schneider, Christian A.
    Pfister, Roman
    HERZ, 2022, 47 (05) : 395 - 400
  • [49] Uptake of SGLT2i and Outcomes in Patients with Diabetes and Heart Failure: A Population-Based Cohort and a Specialized Clinic Cohort
    Gagnon, Luke R.
    Hazra, Deepan
    Perera, Kevin
    Wang, Kaiming
    Kashyap, Niharika
    Sadasivan, Chandu
    Youngson, Erik
    Chu, Luan
    Dover, Douglas C.
    Kaul, Padma
    Simpson, Scot
    Bello, Aminu
    McAlister, Finlay A.
    Oudit, Gavin Y.
    AMERICAN HEART JOURNAL, 2024, 274 : 11 - 22
  • [50] RATIONALE AND DESIGN OF EFI-CHF (ENDOTHELIAL FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE TREATED BY SGLT2I)STUDY
    Di Nunno, Nicola
    D'alessandro, Damiano
    Granatiero, Michele
    Tricarico, Lucia
    Mazzeo, Pietro
    Ceci, Vincenzo
    Amatruda, Marco
    Pugliese, Rosanna
    Alfieri, Simona
    Croella, Francesca
    Mallardi, Adriana
    Leopizzi, Alessandra
    Correale, Michele
    Iacoviello, Massimo
    Di Biase, Matteo
    Stabile, Eugenio
    Brunetti, Natale D.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
12345